Wire · opportunities
Karmanos now offers FDA-approved Daraxonrasib (Rasonque) for metastatic pancreatic cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The Barbara Ann Karmanos Cancer Institute now offers FDA-approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have failed prior systemic therapy or are ineligible for multiagent chemotherapy. The phase III RASolute 302 trial demonstrated daraxonrasib significantly improved median overall survival compared to standard chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You can now expand pancreatic cancer treatment options beyond chemotherapy using FDA-approved daraxonrasib, potentially improving patient outcomes. Oncologists and biotech founders should prioritise partnerships that integrate this targeted oral therapy into care pathways.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Topics